eRapa
Familial Adenomatous Polyposis (FAP)
Key Facts
About Biodexa Pharmaceuticals
Biodexa Pharmaceuticals is a clinical-stage biotechnology company leveraging proprietary drug delivery technologies to improve the performance of existing therapeutic agents. Its strategy centers on reformulating known drugs using nanotechnology and pH-sensitive polymers to enhance bioavailability and pharmacokinetics, thereby de-risking development. The company's pipeline is advancing towards a pivotal Phase 3 trial for eRapa in FAP, while also exploring molecular glue degraders for resistant cancers and a novel therapy for type 1 diabetes. With an experienced leadership team, Biodexa aims to address significant unmet needs in oncology and rare diseases.
View full company profileAbout Biodexa Pharmaceuticals
Biodexa Pharmaceuticals is a clinical-stage biotechnology company leveraging proprietary drug delivery technologies to improve the performance of existing therapeutic agents. Its strategy centers on reformulating known drugs using nanotechnology and pH-sensitive polymers to enhance bioavailability and pharmacokinetics, thereby de-risking development. The company's pipeline is advancing towards a pivotal Phase 3 trial for eRapa in FAP, while also exploring molecular glue degraders for resistant cancers and a novel therapy for type 1 diabetes. With an experienced leadership team, Biodexa aims to address significant unmet needs in oncology and rare diseases.
View full company profileAbout Emtora Biosciences
Emtora Biosciences, founded in 2019, is a private biotech company commercializing eRapa™, a proprietary formulation of the mTOR inhibitor rapamycin. The company's strategy targets cancer prevention and treatment in rare genetic diseases and specific early-stage cancers, addressing significant unmet needs in areas like FAP and non-muscle invasive bladder cancer. As a pre-revenue, development-stage company, its success hinges on clinical validation of eRapa™. The company operates with a lean structure, leveraging the well-established biology of rapamycin to potentially de-risk and accelerate its development pathway.
View full company profileAbout Emtora Biosciences
Emtora Biosciences, founded in 2019, is a private biotech company commercializing eRapa™, a proprietary formulation of the mTOR inhibitor rapamycin. The company's strategy targets cancer prevention and treatment in rare genetic diseases and specific early-stage cancers, addressing significant unmet needs in areas like FAP and non-muscle invasive bladder cancer. As a pre-revenue, development-stage company, its success hinges on clinical validation of eRapa™. The company operates with a lean structure, leveraging the well-established biology of rapamycin to potentially de-risk and accelerate its development pathway.
View full company profileAbout Emtora Biosciences
Emtora Biosciences, founded in 2019, is a private biotech company commercializing eRapa™, a proprietary formulation of the mTOR inhibitor rapamycin. The company's strategy targets cancer prevention and treatment in rare genetic diseases and specific early-stage cancers, addressing significant unmet needs in areas like FAP and non-muscle invasive bladder cancer. As a pre-revenue, development-stage company, its success hinges on clinical validation of eRapa™. The company operates with a lean structure, leveraging the well-established biology of rapamycin to potentially de-risk and accelerate its development pathway.
View full company profileOther Familial Adenomatous Polyposis (FAP) Drugs
| Drug | Company | Phase |
|---|---|---|
| Flynpovi™ (CPP-1X/sulindac) | Panbela Therapeutics | Phase 3 |
| Global Early Access Program for eRapa (with Biodexa) | Tanner Pharma Group | N/A (Early Access Program) |